



an Open Access Journal by MDPI

## New Insights into Upper Tract Urothelial Carcinoma: What Changed?

Guest Editors:

### Dr. Sisto Perdonà

Istituto Nazionale Tumori di  
Napoli, IRCCS “Fondazione G.  
Pascale”, Via M. Semmola, 80131  
Naples, Italy

### Dr. Antonio Tufano

Department of Maternal-Child  
and Urological Sciences,  
Policlinico Umberto I Hospital,  
Sapienza University Rome, 00162  
Rome, Italy

Deadline for manuscript  
submissions:

**30 November 2024**

### Message from the Guest Editors

Upper-tract urothelial carcinoma (UTUC) is an aggressive disease that is managed by radical or organ-sparing surgery. Upper-tract urothelial cancer (UTUC) lacks high-quality evidence to appraise current patterns of presentation, diagnosis, treatment and outcomes as a result of disease rarity and patient heterogeneity. The goal is to obtain a curative setting after diagnosis and primary surgery for UTUC, which can be achieved through accurate and close FU. The impact of standardized regular surveillance on better oncological prognosis has already been investigated in several malignancies, including primary urothelial cancer of the bladder. This again considers the objective for regular surveillance in UTUC to achieve a better outcome based on early recurrence detection. To achieve this, the implementation of prospective randomized studies remains unfeasible, thus giving retrospective studies with standardized strict follow-up protocols a key imperative role.

This Special Issue presents up-to-date summaries related to the pathogenesis, diagnosis, prognostic assessment and management of UTUC.



[mdpi.com/si/173757](https://mdpi.com/si/173757)



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)